Artículos

Selección de artículos (clasificados por temas) sobre los múltiples vértices y planos de la relación entre la industria farmacéutica y la profesión médica. Estos artículos se encuentran disponibles a través de enlaces de acceso libre.

 

INTRODUCCIÓN GENERAL:

Rev GPU. 2011 Mar 7;1:92-102
La industria farmacéutica y su influencia en la práctica clínica.
Santa Cruz P. [leer]

Rev GPU. 2013; 9; 4: 427-435
Médicos bajo la influencia: psicología social y estrategias de marketing de la industria.
Sah S, Fugh-Berman A. [leer]

Rev Méd Chile 2003;131:1463-1468
El médico y los conflictos de intereses.
Lama A. [leer]

BMJ. 2003 May 31;326(7400):1155-6.
No more free lunches.
Abbasi K, Smith R. [leer]

Med J Aust. 2004 Apr 19;180(8):409-10.
The medical profession and the pharmaceutical industry: when will we open our eyes?
Breen KJ. [leer]

PLoS Med. 2009 Jul 21;6(7):e1000075.
Can the relationship between doctors and drug companies ever be a healthy one? (debate)
D’Arcy E, Moynihan R. [leer]

CMAJ. 2004 Dec 7;171(12):1451-3.
Excess in the pharmaceutical industry.
Angell M. [leer]

EDUCACIÓN MÉDICA CONTINUA:

Rev Med Chil. 2013 May;141(5):674-5.
Los congresos médicos de especialidades: algunas reflexiones.
Lama A. [leer]

JAMA. 2012 Mar 28;307(12):1257-8.
Are medical conferences useful? And for whom?
Ioannidis JP. [leer]

JAMA. 2001 Apr 18;285(15):2009-12.
Separating continuing medical education from pharmaceutical marketing.
Relman AS. [leer]

J Law Med Ethics. 2009 Fall;37(3):451-60, 396.
Pharmaceutical industry financial support for medical education: benefit, or undue influence?
Brody H. [leer]

J Med Educ. 1961 Jan;36:1-23.
Selling drugs by “educating” physicians.
May CD. [leer]

Hastings Cent Rep. 2004 Sep-Oct;34(5):18-23.
Pharma goes to the laundry: Public relations and the business of medical education.
Elliott C. [leer]

 

EXPERTOS & LÍDERES DE OPINIÓN:

BMJ. 2008 Jun 21;336(7658):1404.
Should the drug industry work with key opinion leaders? Yes.
Buckwell C. [leer]

BMJ. 2008 Jun 21;336(7658):1405.
Should the drug industry work with key opinion leaders? No.
Fava GA. [leer]

BMJ. 2008 Jun 21;336(7658):1402-3.
Key opinion leaders: independent experts or drug representatives in disguise?
Moynihan R. [leer]

The New York Times. Nov 25, 2007.
Dr. Drug Rep
Carlat D. [leer]

BMJ. 2011 Oct 11;343:d5621.
Prevalence of financial conflicts of interest among panel members producing clinical
practice guidelines in Canada and United States: cross sectional study.

Neuman J, Korenstein D, Ross JS, Keyhani S. [leer]

BMJ. 2011 May 3;342:d2548.
Medicalization. A new deal on disease definition.
Moynihan R. [leer]

INVESTIGACIÓN & DIVULGACIÓN:

JAMA. 2017 May 2;317(17):1774-1784.
Types and Distribution of Payments From Industry to Physicians in 2015
Tringale K, Marshall D, Mackey T, Connor M, Murphy J, Hattangadi-Gluth J. [leer]

JAMA. 2008 Sep 3;300(9):1069-71.
Industry-sponsored clinical research: a broken system.
Angell M. [leer]

PLoS Med. 2008 Nov 25;5(11):e217.
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
Rising K, Bacchetti P, Bero L. [leer]

PLoS Med. 2007 Sep;4(9):e286.
Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?
Sismondo S. [leer]

JAMA. 2006 Aug 23;296(8):996-8.
The influence of money on medical science.
DeAngelis CD. [leer]

BMJ. 2003 May 31;326(7400):1202-5.
Medical journals and pharmaceutical companies: uneasy bedfellows.
Smith R. [leer]

PLoS Med. 2005 May;2(5):e138. Epub 2005 May 17.
Medical journals are an extension of the marketing arm of pharmaceutical companies.
Smith R. [leer]

 

VISITAS & OBSEQUIOS:

PLoS Med. 2007;4:e150
Following the script: how drug reps make friends and influence doctors.
Fugh-Berman A, Ahari S. [leer]

Ann Fam Med. 2005 Jan-Feb;3(1):82-5.
The company we keep: why physicians should refuse to see pharmaceutical representatives.
Brody H. [leer]

BMJ. 1999 Jul 10;319(7202):69-70
Reasons for not seeing drug representatives.
Griffith D. [leer]

BMJ. 2010 Mar 29;340:c1102
My year without drug reps.
O’Hanlon S.  [leer]

J Gen Intern Med. 2007 Feb;22(2):184-90.
Physicians and drug representatives: exploring the dynamics of the relationship.
Chimonas S, Brennan TA, Rothman DJ. [leer]

J Surg Res. 2007 Jun 1;140(1):1-5.
The devil is in the details: the pharmaceutical industry’s use of gifts to physicians as marketing strategy.
McFadden DW, Calvario E, Graves C. [leer]

Blog PostPsiquiatría. Abril 2012.
Razones para no aceptar un bolígrafo (u otras cosillas).
García-Valdecasas J. [leer]

J Rheumatol. 2004 Aug;31(8):1478-82.
Why I no longer accept pens (or other “gifts”) from industry (and why you shouldn’t either).
Panush RS. [leer]

MEDICINA BASADA EN EVIDENCIA & JUICIO CLÍNICO:

Indian J Med Res. 2010 Nov;132:623-6.
Clinical judgement & evidence-based medicine: time for reconciliation.
Karthikeyan G, Pais P. [leer]

BMJ. 1996 Jan 13;312(7023):71-2.
Evidence based medicine: what it is and what it isn’t.
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. [leer]

Arch Intern Med. 2011 Sep 12;171(16):1433-40.
Principles of conservative prescribing.
Schiff GD, Galanter WL, Duhig J, Lodolce AE, Koronkowski MJ, Lambert BL. [leer]

Harvard Health Policy Rev. 2007 Spring; vol 8 nº1:145-55
Corruption of the evidence as threat and opportunity for evidence-based medicine.
V Montori, GH Guyatt. [leer]